UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2010
NUVASIVE, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
Delaware
(State or Other Jurisdiction of
Incorporation)
|
|
000-50744
(Commission File
Number)
|
|
33-0768598
(I.R.S. Employer Identification
Number) |
7475 Lusk Boulevard, San Diego, California 92121
(Address of principal executive offices, with zip code)
(858) 909-1800
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other Events.
As previously disclosed, a trial was set for September 2010 for a case against NuVasive, Inc., a Delaware corporation (the “Company”), in the Central District of California (Case No. 2:09-cv-06988-R-JEM) involving alleged trademark infringement and unfair competition. An unfavorable verdict from the U.S. District Court for the Central District of California was delivered against the Company in its use of the NeuroVision name. NuVasive intends to timely appeal the decision.
The Company’s press release is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| 99.1 |
|
Press release issued by NuVasive, Inc. on October 27, 2010.
|